1 2 Superpharm Bolton Ltd 09449153 false 2023-08-01 2024-07-31 2024-07-31 The principal activity of the company is that of a holding company. Digita Accounts Production Advanced 6.30.9574.0 true true 09449153 2023-08-01 2024-07-31 09449153 2024-07-31 09449153 core:FinancialAssetsCostLessImpairment core:Non-currentFinancialInstruments 2024-07-31 09449153 core:CurrentFinancialInstruments 2024-07-31 09449153 core:CurrentFinancialInstruments core:WithinOneYear 2024-07-31 09449153 core:Non-currentFinancialInstruments 2024-07-31 09449153 core:Non-currentFinancialInstruments core:AfterOneYear 2024-07-31 09449153 bus:SmallEntities 2023-08-01 2024-07-31 09449153 bus:AuditExemptWithAccountantsReport 2023-08-01 2024-07-31 09449153 bus:FilletedAccounts 2023-08-01 2024-07-31 09449153 bus:SmallCompaniesRegimeForAccounts 2023-08-01 2024-07-31 09449153 bus:RegisteredOffice 2023-08-01 2024-07-31 09449153 bus:Director2 2023-08-01 2024-07-31 09449153 bus:PrivateLimitedCompanyLtd 2023-08-01 2024-07-31 09449153 countries:EnglandWales 2023-08-01 2024-07-31 09449153 2022-08-01 2023-07-31 09449153 2023-07-31 09449153 core:CurrentFinancialInstruments 2023-07-31 09449153 core:CurrentFinancialInstruments core:WithinOneYear 2023-07-31 09449153 core:Non-currentFinancialInstruments 2023-07-31 09449153 core:Non-currentFinancialInstruments core:AfterOneYear 2023-07-31 xbrli:pure iso4217:GBP

Registration number: 09449153

Superpharm Bolton Ltd

Unaudited Filleted Financial Statements

for the Year Ended 31 July 2024

 

Superpharm Bolton Ltd

Contents

Balance Sheet

1 to 2

Notes to the Financial Statements

3 to 6

 

Superpharm Bolton Ltd

(Registration number: 09449153)
Balance Sheet as at 31 July 2024

Note

2024
£

2023
£

Fixed assets

 

Other financial assets

4

1,814,134

1,814,134

Current assets

 

Debtors

5

-

38,500

Cash at bank and in hand

 

5,499

6,586

 

5,499

45,086

Creditors: Amounts falling due within one year

6

(582,373)

(595,010)

Net current liabilities

 

(576,874)

(549,924)

Total assets less current liabilities

 

1,237,260

1,264,210

Creditors: Amounts falling due after more than one year

6

(897,059)

(1,011,280)

Net assets

 

340,201

252,930

Capital and reserves

 

Called up share capital

41

41

Capital redemption reserve

61

61

Retained earnings

340,099

252,828

Shareholders' funds

 

340,201

252,930

 

Superpharm Bolton Ltd

(Registration number: 09449153)
Balance Sheet as at 31 July 2024

For the financial year ending 31 July 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the director on 4 April 2025
 

.........................................
Mr I Khan
Director

 

Superpharm Bolton Ltd

Notes to the Financial Statements for the Year Ended 31 July 2024

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
150 Deane Road
Bolton
BL3 5DL
England

These financial statements were authorised for issue by the director on 4 April 2025.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Going concern

Business combinations

Business combinations are accounted for using the purchase method. The consideration for each acquisition is measured at the aggregate of the fair values at acquisition date of assets given, liabilities incurred or assumed, and equity instruments issued by the group in exchange for control of the acquired, plus any costs directly attributable to the business combination. When a business combination agreement provides for an adjustment to the cost of the combination contingent on future events, the group includes the estimated amount of that adjustment in the cost of the combination at the acquisition date if the adjustment is probable and can be measured reliably.

Intangible assets

Intangible assets will be reviewed annually for any impairment of the investment.

 

Superpharm Bolton Ltd

Notes to the Financial Statements for the Year Ended 31 July 2024

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

3

Staff numbers

The average number of persons employed by the company (including the director) during the year, was 1 (2023 - 2).

4

Other financial assets (current and non-current)

Financial assets at cost less impairment
£

Total
£

Non-current financial assets

Cost or valuation

At 1 August 2023

1,814,134

1,814,134

At 31 July 2024

1,814,134

1,814,134

Impairment

Carrying amount

At 31 July 2024

1,814,134

1,814,134

 

Superpharm Bolton Ltd

Notes to the Financial Statements for the Year Ended 31 July 2024

5

Debtors

Current

2024
£

2023
£

Other debtors

-

38,500

 

-

38,500

6

Creditors

Creditors: amounts falling due within one year

Note

2024
£

2023
£

Due within one year

 

Loans and borrowings

7

70,134

66,767

Amounts owed to group undertakings and undertakings in which the company has a participating interest

49,256

6,160

Taxation and social security

 

462,983

521,483

Accruals and deferred income

 

-

600

 

582,373

595,010

Creditors include bank loans which are secured of £70,134 (2023 - £66,767).

Creditors: amounts falling due after more than one year

Note

2024
£

2023
£

Due after one year

 

Loans and borrowings

7

897,059

1,011,280


Creditors include bank loans which are secured of £897,059 (2023 - £1,011,280).

A debenture has been lodged at Companies House, in favour of Natwest bank, with fixed and floating charges over all assets, dated 14 August 2015.

 

Superpharm Bolton Ltd

Notes to the Financial Statements for the Year Ended 31 July 2024

7

Loans and borrowings

Non-current loans and borrowings

2024
£

2023
£

Bank borrowings

897,059

1,011,280

Current loans and borrowings

2024
£

2023
£

Bank borrowings

70,134

66,767